MedTrace Logo

Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)

NCT00439257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2015-04-07

No results posted yet for this study

Summary

The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding the pathogenesis of the inflammatory demyelinating process. The result was to raise new issues in the treatment of the disease, which are then being addressed by studies, including when to initiate treatment and the treatment of partial responders to existing therapies. Paralleling strides in treatment, and of particular importance to the Veterans Administration, was the effectiveness of such therapies, both in terms of cost to the VA Health Care System and quality of life of veterans with multiple sclerosis. This study addressed these issues.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Joseph B. Guarnaccia, MD · VA Connecticut Healthcare System West Haven Campus, West Haven, CT

  • Robert M. Baumhefner, MD · VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2000-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439257 on ClinicalTrials.gov